Beijing Doing Biomedical Co., Ltd.

Quick facts

Phase 1 pipeline

• anti-CD19 anti-CD20 Bispecific CAR-T
• Anti-CD19-CAR γδT
• CIK and γδ T
• MUC1-gene-DC-CTL
• MUC1-peptide-DC-CTL

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Beijing Doing Biomedical Co., Ltd. portfolio CI brief
• Beijing Doing Biomedical Co., Ltd. pipeline updates RSS